|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Devesa SS, Bray F, Vizcaino AP and Parkin
DM: International lung cancer trends by histologic type:
Male:Female differences diminishing and adenocarcinoma rates
rising. Int J Cancer. 117:294–299. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Sementchenko VI and Watson DK: Ets target
genes: Past, present and future. Oncogene. 19:6533–6548. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Seth A and Watson DK: ETS transcription
factors and their emerging roles in human cancer. Eur J Cancer.
41:2462–2478. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wasylyk B, Hagman J and Gutierrez-Hartmann
A: Ets transcription factors: Nuclear effectors of the
Ras-MAP-kinase signaling pathway. Trends Biochem Sci. 23:213–216.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Trojanowska M: Ets factors and regulation
of the extracellular matrix. Oncogene. 19:6464–6471. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Benz CC, O'Hagan RC, Richter B, Scott GK,
Chang CH, Xiong X, Chew K, Ljung BM, Edgerton S, Thor A and Hassell
JA: HER2/Neu and the Ets transcription activator PEA3 are
coordinately upregulated in human breast cancer. Oncogene.
15:1513–1525. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Eckel KL, Tentler JJ, Cappetta GJ, Diamond
SE and Gutierrez-Hartmann A: The epithelial-specific ETS
transcription factor ESX/ESE-1/Elf-3 modulates breast
cancer-associated gene expression. DNA Cell Biol. 22:79–94. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kas K, Finger E, Grall F, Gu X, Akbarali
Y, Boltax J, Weiss A, Oettgen P, Kapeller R and Libermann TA:
ESE-3, a novel member of an epithelium-specific ets transcription
factor subfamily, demonstrates different target gene specificity
from ESE-1. J Biol Chem. 275:2986–2998. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kleinbaum LA, Duggan C, Ferreira E, Coffey
GP, Buttice G and Burton FH: Human chromosomal localization,
tissue/tumor expression, and regulatory function of the ets family
gene EHF. Biochem Biophys Res Commun. 264:119–126. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Cangemi R, Mensah A, Albertini V, Jain A,
Mello-Grand M, Chiorino G, Catapano CV and Carbone GM: Reduced
expression and tumor suppressor function of the ETS transcription
factor ESE-3 in prostate cancer. Oncogene. 27:2877–2885. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Shaikhibrahim Z, Lindstrot A, Langer B,
Buettner R and Wernert N: Differential expression of ETS family
members in prostate cancer tissues and androgen-sensitive and
insensitive prostate cancer cell lines. Int J Mol Med. 28:89–93.
2011.PubMed/NCBI
|
|
14
|
Turcotte S, Forget MA, Beauseigle D,
Nassif E and Lapointe R: Prostate-derived Ets transcription factor
overexpression is associated with nodal metastasis and hormone
receptor positivity in invasive breast cancer. Neoplasia.
9:788–796. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Brenne K, Nymoen DA, Hetland TE, Trope CG
and Davidson B: Expression of the Ets transcription factor EHF in
serous ovarian carcinoma effusions is a marker of poor survival.
Hum Pathol. 43:496–505. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Hynes NE and MacDonald G: ErbB receptors
and signaling pathways in cancer. Curr Opin Cell Biol. 21:177–184.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Gelsomino F, Facchinetti F, Haspinger ER,
Garassino MC, Trusolino L, De Braud F and Tiseo M: Targeting the
MET gene for the treatment of non-small-cell lung cancer. Crit Rev
Oncol Hematol. 89:284–299. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhang S, Gao L, Thakur A, Shi P, Liu F,
Feng J, Wang T, Liang Y, Liu JJ, Chen M and Ren H: MiRNA-204
suppresses human non-small cell lung cancer by targeting ATF2.
Tumour Biol. 37:11177–11186. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wang P, Henning SM and Heber D:
Limitations of MTT and MTS-based assays for measurement of
antiproliferative activity of green tea polyphenols. PLoS One.
5:e102022010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Shi J, Liu W, Sui F, Lu R, He Q, Yang Q,
Lv H, Shi B and Hou P: Frequent amplification of AIB1, a critical
oncogene modulating major signaling pathways, is associated with
poor survival in gastric cancer. Oncotarget. 6:14344–14359. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Hollenhorst PC, Jones DA and Graves BJ:
Expression profiles frame the promoter specificity dilemma of the
ETS family of transcription factors. Nucleic Acids Res.
32:5693–5702. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Roskoski R Jr: The ErbB/HER family of
protein-tyrosine kinases and cancer. Pharmacol Res. 79:34–74. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Holbro T, Civenni G and Hynes NE: The ErbB
receptors and their role in cancer progression. Exp Cell Res.
284:99–110. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Roskoski R Jr: The ErbB/HER receptor
protein-tyrosine kinases and cancer. Biochem Biophys Res Commun.
319:1–11. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Petrini I: Biology of MET: A double life
between normal tissue repair and tumor progression. Ann Transl Med.
3:822015.PubMed/NCBI
|
|
27
|
Cappuzzo F, Marchetti A, Skokan M, Rossi
E, Gajapathy S, Felicioni L, Del Grammastro M, Sciarrotta MG,
Buttitta F, Incarbone M, et al: Increased MET gene copy number
negatively affects survival of surgically resected non-small-cell
lung cancer patients. J Clin Oncol. 27:1667–1674. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Fu P, Du F, Yao M, Lv K and Liu Y:
MicroRNA-185 inhibits proliferation by targeting c-Met in human
breast cancer cells. Exp Ther Med. 8:1879–1883. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Hagman Z, Haflidadottir BS, Ansari M,
Persson M, Bjartell A, Edsjö A and Ceder Y: The tumour suppressor
miR-34c targets MET in prostate cancer cells. Br J Cancer.
109:1271–1278. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Phan LM, Fuentes-Mattei E, Wu W,
Velazquez-Torres G, Sircar K, Wood CG, Hai T, Jimenez C, Cote GJ,
Ozsari L, et al: Hepatocyte Growth Factor/cMET pathway activation
enhances cancer hallmarks in adrenocortical carcinoma. Cancer Res.
75:4131–4142. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Maroun CR and Rowlands T: The Met receptor
tyrosine kinase: A key player in oncogenesis and drug resistance.
Pharmacol Ther. 142:316–338. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Engelman JA, Zejnullahu K, Mitsudomi T,
Song Y, Hyland C, Park JO, Lindeman N, Gale CM, Zhao X, Christensen
J, et al: MET amplification leads to gefitinib resistance in lung
cancer by activating ERBB3 signaling. Science. 316:1039–1043. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Karamouzis MV, Konstantinopoulos PA and
Papavassiliou AG: Targeting MET as a strategy to overcome
crosstalk-related resistance to EGFR inhibitors. Lancet Oncol.
10:709–717. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Troiani T, Martinelli E, Napolitano S,
Vitagliano D, Ciuffreda LP, Costantino S, Morgillo F, Capasso A,
Sforza V, Nappi A, et al: Increased TGF-α as a mechanism of
acquired resistance to the anti-EGFR inhibitor cetuximab through
EGFR-MET interaction and activation of MET signaling in colon
cancer cells. Clin Cancer Res. 19:6751–6765. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Luk IY, Reehorst CM and Mariadason JM:
ELF3, ELF5, EHF and SPDEF transcription factors in tissue
homeostasis and cancer. Molecules. 23:21912018. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Cheng Z, Guo J, Chen L, Luo N, Yang W and
Qu X: Knockdown of EHF inhibited the proliferation, invasion and
tumorigenesis of ovarian cancer cells. Mol Carcinog. 55:1048–1059.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Fossum SL, Mutolo MJ, Yang R, Dang H,
O'Neal WK, Knowles MR, Leir SH and Harris A: Ets homologous factor
regulates pathways controlling response to injury in airway
epithelial cells. Nucleic Acids Res. 42:13588–13598. 2014.
View Article : Google Scholar : PubMed/NCBI
|
